# MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis

> **NCT01497223** · PHASE2 · COMPLETED · sponsor: **MethylGene Inc.** · enrollment: 220 (actual)

## Conditions studied

- Vulvovaginal Candidiasis

## Interventions

- **DRUG:** MGCD290

## Key facts

- **NCT ID:** NCT01497223
- **Lead sponsor:** MethylGene Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2013-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01497223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01497223, "MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01497223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*